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Abstract
Objective: To determine the safety and logistic feasibility of a mass immunization strategy outside
the local immunization program in the pediatric population of urban squatter settlements in
Karachi, Pakistan.
Methods: A cluster-randomized double blind preventive trial was launched in August 2003 in 60
geographic clusters covering 21,059 children ages 2 to 16 years. After consent was obtained from
parents or guardians, eligible children were immunized parenterally at vaccination posts in each
cluster with Vi polysaccharide or hepatitis A vaccine. Safety, logistics, and standards were
monitored and documented.
Results: The vaccine coverage of the population was 74% and was higher in those under age 10
years. No life-threatening serious adverse events were reported. Adverse events occurred in less
than 1% of all vaccine recipients and the main reactions reported were fever and local pain. The
proportion of adverse events in Vi polysaccharide and hepatitis A recipients will not be known until
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the end of the trial when the code is broken. Throughout the vaccination campaign safe injection
practices were maintained and the cold chain was not interrupted. Mass vaccination in slums had
good acceptance. Because populations in such areas are highly mobile, settlement conditions could
affect coverage. Systemic reactions were uncommon and local reactions were mild and transient.
Close community involvement was pivotal for information dissemination and immunization
coverage.
Conclusion: This vaccine strategy described together with other information that will soon be
available in the area (cost/effectiveness, vaccine delivery costs, etc) will make typhoid fever control
become a reality in the near future.

Background
Despite major breakthroughs in the development of new
vaccines over the past two decades, the gap in access to
vaccines between wealthy and poorer countries has widened. As a result, immunization schedules offer more vaccines in high-income countries than in those with low
income [1]. Children in low-income countries are also at
a disadvantage because vaccine research and development
agendas are tailored to the needs of developed countries.
The focus the International Vaccine Institute typhoid fever
program is to enable people at risk to get access to the vaccines and decrease the burden of typhoid fever [2]. The
program is being conducted in five urban slums of Indonesia, China, Vietnam, India and Pakistan.
Two typhoid fever vaccines, Ty21a and Vi polysaccharide
(PS) are currently licensed for use. A recent Cochrane
review [3] on typhoid fever vaccines found that the two
vaccines i.e. Ty 21 and Vi have similar results with Vi having an advantage of heat stability and single dose regimen.
ViPS was thus chosen for use in the DOMI trial as it would
suit the public health program for immunization in the
countries of south east Asia. The use of Vi requiring a single, injectable dose was thought to be logistically easier
than use of Ty21 which requires three doses.
In Pakistan, DOMI program aims to introduce an available, affordable Vi polysaccharide vaccine [4,5] for children 2 to 16 years of age living in urban low socio
economic settings. The study setting has a high typhoid
fever burden and treatment is increasingly costly [6] and
difficult due to high drug resistance[7,8]. Vi PS vaccine,
which has moderate efficacy (64–77%), seems to be an
immediate and affordable option for impoverished populations exposed to typhoid fever[9]. Unfortunately, there
is no evidence about its cost-effectiveness and no delivery
strategy has been envisaged that would enable policymakers to make rational decisions about the use of this vaccine
as a public health tool.
To determine the effectiveness of Vi PS in reducing
typhoid fever burden in slum areas and the cost-effectiveness of the vaccine, DOMI investigators designed a clus-

ter-randomized double blind trial [2]. Given the apparent
immunological limitation of PS vaccines in early age
groups [10] and the fact that the high-risk group in Karachi is the entire pediatric population, the local Expanded
Program of Immunization (EPI), which usually reaches
children under age 5 years, is unlikely to be the best delivery structure. Also, national reported immunization coverage rates for Pakistan have been very variable (range of
60–90%) since 1998 [11]. In addition to a lack of
resources, other documented reasons for low vaccine coverage in Pakistan include lack of awareness of need, mothers unable to attend the vaccine posts, and inconvenient
immunization sites [12-14] For these reasons, the DOMI
program decided to implement the mass immunization
campaign outside the EPI delivery system. Here we report
initial results from this mass vaccination in two slums in
Karachi, Pakistan.

Methods
Study site
The vaccination campaign was carried out in two adjacent
squatter settlements, Sultanabad and Hijrat Colony, in
Karachi. The population is a mix of Punjabi-Pathan ethnic
groups from northern Pakistan. The total population of
the two areas is 53,738 (project census 2003), with 21,059
children (aged 2–16 years) in the study target pediatric
population. There are 8,278 households in the combined
settlement areas of 0.54 km2. Most health-care is provided
by the private sector through small clinics. In the last 7
years the Department of Pediatrics of Aga Khan University
[7] has rendered free clinical services to the pediatric population through health centers, one in each study area.
These are staffed with research medical officers (RMO),
health assistants, field supervisors, and community health
workers (CHW). The study area is considered to be a high
endemic area for typhoid fever, especially among children
[6,15].
Sample size
A total of approximately 24,710 children are needed in
order to have 80% power to detect a 50% vaccine protection at a 5% level of significance. Using Hayes and Bennet
formula [16], this sample size calculation assumes a minPage 2 of 10
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imum cumulative typhoid incidence of 2.8 per 1000 (during 2 years), assuming alpha = 0.05, minimum power 0.8
(= 1-beta) to achieve a significant difference, Protective
Efficacy (PE) of 0.5 for 2 years, between cluster coefficient
of variation (CV) below 0.5 an average cluster size of 580.
Study design
The cluster-randomized design employed by the trial
mimics the way Vi vaccine would be delivered under a
public health program in Pakistan. The study area, Sultanabad and Hijrat Colony were divided into 28 and 32 geographic clusters (a group of adjacent households),
respectively (figure 2). Cluster sizes varied from 162 to
653 children (2–16 years of age) with an average of 350.
The unit of randomization (clusters) was stratified by
slum (Hijrat or Sultanabad) and cluster size (large of
small). The eligible population was children aged 2–16
years who were included in the project census and whose
parents/guardians gave consent to participate. These 60
geographic areas (clusters, 32 in Hijrat colony and 28 in
Sultanabad) were randomly allocated to Vi PS vaccine
(Typherix®) or the active control hepatitis A vaccine
(Havrix®). Randomization was done by an expert statistician who was independent of disease surveillance activities in the study setting. The local investigators were not
aware which vaccine was assigned codes (C & M). Labeling of the vaccine was done by the vaccine producer in
Rixensart, Belgium. The randomization sequence was not
changed at any level once it was initially generated. Each
team worked with the single code throughout the campaign to minimize the risk of mix-ups. The schedule of
cluster visits were arranged in such a way that the number
of vaccine in both groups given per day was approximately equal. Continuous supervisory visits by supervisory team and external monitors ensured that all
procedures were followed according to the protocol.
The vaccines
Both vaccines, ViPS and HAV, are licensed in Pakistan and
were donated by GlaxoSmithKline (GSK). Similar individual-dose-syringe vaccines were labelled with information
on: the batch number, expiry date, route of administration and code (C or M). The identification of codes was
kept with the Data Safety and Monitoring Board (DSMB).
Each 0.5 ml dose of Typherix® contained 25 micrograms of
the Vi PS of S. Typhi. Each 0.5 ml of pediatric dose of
Havrix® vaccine consists of not less than 720 units of viral
antigen, adsorbed on 0.25 mg aluminum hydroxide. The
Havrix® dosage consisted of a primary course and a
booster that will be administered after the study ends
(year 2). Both vaccines are for intramuscular injection
only. Both groups will ultimately receive the benefits of
the Vi vaccine as well as the HAV vaccine as a cross-over
vaccination is planned at the end of the surveillance
period.

http://www.trialsjournal.com/content/7/1/17

In case of an adverse event the physician in charge examined the vaccine recipients and assess the severity of the
event. In case of an event requiring hospitalization, the
clinical monitor was notified who visited the patient and
assessed the need of breaking the code after managing the
case.
This project was approved by the AKU (Karachi) ethical
committee, the Institutional Review Board of the International Vaccine Institute (IVI), Seoul, and the World Health
Organization (WHO) ethical committee. A Data Safety
and Monitoring Board (DSMB) was established for the
audit, protocol review and take a decision on breaking the
codes in case the breaking of code was deemed necessary
due to an adverse event.
Information dissemination and consent
Information dissemination started 12 weeks before the
campaign. Sessions at street level were conducted by
Research Medical Officers (RMO) or trained female Community Health Workers (CHW), as appropriate, and
focused on the importance of immunization against
typhoid fever and other control measures. More intense
promotion of the campaign began in June 2003, 4 weeks
prior to the campaign, by a team of RMOs and social scientists, who conducted meetings with community and
religious leaders, members of local government bodies,
and street representatives. Information leaflets were distributed and announcements were made at local
mosques. Suitable areas for vaccination posts in each cluster were identified. The day before the vaccination date,
households were visited and given formal invitation letters that included the site, date, and time for vaccination.
During the campaign repeated visits were made by CHWs
to remind and motivate those targeted for vaccination.

Parents and guardians visiting vaccination posts on the
day of immunization were given information about the
nature of the trial, expected risks and benefits, and procedural details as part of the informed consent. Trained
project personnel provided this information. Upon agreeing to participate, a thumbprint was affixed on the vaccination record book together with the signature of a
witness.
Training and logistics
Vaccination teams received intensive training that focused
on the trial's primary objectives, public health implications, blinding, cold chain maintenance, adverse events
(AE), and community mobilization. Good Clinical Practices (GCPs) were emphasized at every step of training
and monitored throughout the campaign. An adverse
event was defined as a medical incident that takes place
after vaccination, causes concern and is believed to be
caused by the immunization. Continuous feedback meet-
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Assessed for eligibility
(60clusters)
Excluded
(0)
Randomized (60clusters)
21059 children

Hijrat colony (32 clusters)
Target Population 11607

Sultanabad (28 clusters)
Target Population 9452

Allocated to receive “C” 16 clusters
Received C
Number of clusters 16
Average cluster size 357
Range of cluster size 207 - 652

Allocated to receive “C” 14
Received C
Number of clusters 14
Average cluster size 327
Range of cluster size 162 - 484

Total target population 5707
Total received vaccine 3634 (63.8%)

Total target population 4577
Total received vaccine 2672 (58.4%)

Allocated to receive “M”: (16 clusters)
Received C
Number of clusters
16
Average cluster size
369
Range of cluster size
161– 653

Allocated to receive “M”: (14 clusters)
Received M
Number of clusters 14
Average cluster size 348
Range of cluster size 245– 483

Total target population 5900
Total received vaccine 3526 (59.8%)

Total target population 4875
Total received vaccine 2996 (61.4%)

*The consort flow diagram only shows the distribution of cluster randomization up to the vaccination
campaign (the intervention phase), as the analysis is due after the completion of the trial
Figure 1 of target population and vaccination coverage Vi trial in Karachi Pakistan
Distribution
Distribution of target population and vaccination coverage Vi trial in Karachi Pakistan.
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leaders. Additionally, four local social scientists developed and organized the community awareness of the
campaign. AKU drivers (5) assisted with transportation of
supplies.
Vaccines were transported from Belgium to a local warehouse in Karachi. Recommended storage temperature of
both vaccines is +2°C to +8°C. The temperature was monitored by one or more of the following methods: conventional thermometer, maximum-minimum thermometer,
visual indicators of low temperature (FreezeWatch™, 3 M,
USA), wheel recorders, and automated battery-powered
devices (COX Technology, Sensitech, Inc., Beverly, MA,
USA). Vaccines were stored in several sites: the central
warehouse, the AKU warehouse, a field site logistics
center, and cool boxes at vaccination posts. At the logistics
center an officer distributed the vaccine on a daily basis to
each vaccination team. Temperature was monitored and
documented as follows: constantly at the central warehouse, once a day at the AKU warehouse, twice or more
each day at the logistics center, and in the field (by the
team leader) at least twice a day. Alternate power supply
was available at all storage locales. Cooling equipment at
each storage site consisted of cold rooms, a chest refrigerator at the logistics center, and cool boxes with frozen ice
packs for the vaccination teams. Vaccine usage was
recorded daily on a logistics form.

Figure
Cluster
tion
project
2
wiseKarachi
distribution
– Pakistan
of vaccine
2003codes in Vi demonstraCluster wise distribution of vaccine codes in Vi demonstration project Karachi – Pakistan 2003.

ings were conducted at intervals throughout the campaign.
Ten vaccination teams were employed consisting each of
1 physician, 1 vaccinator, 1 recorder, and 2 or 3 assistants.
All were recruited specifically for the campaign and vaccinators were hired locally from the study sites. Physicians
(team leaders) were responsible for the clinical and logistical components of their respective group. Supervisors
(4) were in charge of two or three teams. External observers (2) monitored and documented key aspects (consent
process, standards, safety, and cold chain) on designated
forms. Seven community members assisted the campaign.
Most of the vaccination posts were rooms or entire homes
provided by residents and agreed upon by community

Immunization campaign
The mass immunization campaign was planned and
launched in a way that it would not disturb other regular
local health programs. Vaccination took place from Monday through Sunday from 3 pm to 11 pm; this timing
allowed the parent/guardian (usually a working male)
flexibility to visit after the working hours. Each vaccination team was in charge of one cluster and was assigned to
deliver one and only one vaccine code letter (C, M). The
chance of breaking the code was reduced by explaining
the purpose of blinding to the teams, rechecking by
another person at the time of distribution and follow up
visits by site supervisors to ensure the same code is being
given in the cluster that is assigned after randomization.
All efforts were made to ensure blinding.

Based on a pre-assigned schedule, vaccination teams visited each cluster from August 12th to September 12th,
2003, to cover the target population of 21,059 children.
Any child with fever > 37.5°C at the time of immunization or a female who was married, pregnant, and/or lactating was considered ineligible. Febrile individuals were
provided with antipyretics and asked to return if the temperature subsided.
A vaccine record book (per cluster) containing a page-bypage alphabetical listing of all household members
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Table 1: Vaccination coverage results from mass vaccination
campaign in urban squatter settlements of Karachi, Pakistan –
2003
Target population

No. of individuals

Not vaccinated
Migrated
Census programmatic error
Total population eligible for vaccination
Vaccinated
Ineligible (fever/pregnancy/etc.)
Absent
Refused
Already received typhoid vaccine

21,059
2,824
895
17,340
12,830
69
1,811
2,613
17

%

13.4
4.2
74.0
0.4
10.4
15.1
0.1

(based on a project census conducted 6 months earlier)
was available to each team. Children were identified by
their project identification (ID) card; if the card was not
available, a computerized ID search system was used. The
record book also documented the date of vaccination, eligibility, letter code of the vaccine, and presence or absence

of an immediate AE. Team assistants (who belonged to
the study area and have been working with AKU for at
least one year) repeatedly visited the households in a specific cluster to re-invite and also to update household status such as migration, refusals, temporary absentees, and
census duplications. The clusters where the vaccine coverage was less than 60% were visited again in the last 4 days
of the campaign by re-establishing the vaccine post.
Vaccination AE data were obtained by direct observation
of each vaccinee at each vaccination center for 30 minutes
to detect immediate serious AE; by home visits (once/day,
total of 3) in a cluster-based random sub-sample of 240
children (4 per cluster) to detect solicited AE; and by passive surveillance of un-solicited AE in the initial 30 days.
Vaccination posts had basic emergency equipment and
trained study staff to treat immediate severe AE (SAE);
transportation to the AKU hospital was assured for SAEs.
WHO guidelines on safe injection practices [17] were followed. Needlestick injuries were reported to the supervisor and treated in accordance with national guidelines.
Disposal boxes for the safe disposal of sharps were provided to each team; the boxes were later incinerated at
AKU hospital.
Outcomes, data management, and statistical analysis
The primary outcome of the trial is an episode of fever
during which S. Typhi is isolated from blood culture or
fever ≥ 3 days and a positive serology-proven typhoid
fever test (Widal test or Tubex or Typhidot-M) or fever ≥ 3
days and a positive Widal test or fever ≥ 24 hours and
body temperature ≥ 38.5C and ≥ 1 of the following symptoms: headache, abdominal pain or constipation and a
positive (Widal or Tubex or Typhidot-M) test.

The denominator for the incidence rate calculations will
be the number of subjects at risk and it will be the primary
denominator used to measure the outcomes.
Analysis of the surveillance data will be based on a fixed
cohort approach and the incidence of typhoid fever in a
two-year period will be calculated. Vaccine coverage was
calculated on the basis of the vaccination record books
and the proportion immunized from the target population. To assess logistics, the following were described and
quantified: (1) resources, including personnel, needed for
vaccine storage, transport, and delivery; (2) efficiency of
vaccine storage, transport, and handling; and (3) safe vaccination practices, including vaccine administration and
disposal of sharps.
Figure wise
Cluster
vaccination
Pakistan
32003
campaign
distribution
in Viofdemonstration
vaccination coverage
projectduring
Karachi
mass
–
Cluster wise distribution of vaccination coverage during mass
vaccination campaign in Vi demonstration project Karachi –
Pakistan 2003.

Data were maintained with a FoxPro 6 (Microsoft, Redmond, WA USA) based data management system. Simple
descriptive statistics such as frequencies, averages estimates, and proportions with standard deviation were cal-
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culated using SPSS version 10 (SPSS Inc., Cary, NC, USA).
ArcView 8 (ESRI, USA) was used for geographical information system analysis.

Results
Vaccine coverage
In total, 12,830 (61%) children were vaccinated during
the campaign. Of the remaining target population of
8,229 who did not receive vaccine, main reasons were
emigration (2,824), refusal to participate (2,613), absence
(1,811), ineligible (69), vaccinated in other programs
(17), and incorrect census data (895) (table 1). The final
coverage in the study sites was 74% with highest coverage
in children aged 2–10 years (77%) and lower in those >10
years (67%). Overall coverage by gender and area was
similar (table 2). Cluster vaccination varied from 37% to
81%, with median cluster coverage of 63% (figure 1). Second visit to the low coverage clusters in the last days
(mop-up) increased the overall coverage from 70% to
74%.
Safety
There were 116 children with AE (<1%) of which 108
were detected by passive surveillance by the vaccination
teams or health center staff. Of the 116 events, 53 were
considered by the study physicians to be probably related
to the vaccines. Among 139 persons surveyed three days
after vaccination, 5 solicited AE were detected and none
was considered a serious event. Three persons were hospitalized post immunization and were managed as an SAE
until the DSMB and clinical monitor labeled them not to
be related with the study vaccines. One child developed
petchial heamorrhges and later was found out to be having a bleeding disorder. Another child was admitted with
fever and was diagnosed as having culture proven
typhoid. The third one had developed an injection
abscess. The main adverse events reported included fever
(48), local pain (56) and local swelling (15). No needle
stick injuries were reported.
Cold chain
There was no important deviation of the cold chain at any
storage site. The central warehouse maintained the vaccine from +5°C to +6°C (mean +5.8°C); the AKU warehouse at +2°C to +8°C (mean 4.8°C), and the logistics
center at +1°C to +12°C (mean 4.8°C). No vaccines were
frozen. Alternate power supply was not needed at any
locale.

The temperatures recorded at the vaccination posts were
+3°C to +20°C (mean +4°C). These were maintained by
4 or 5 ice packs per cool box. The highest temperatures
were observed during the busy hours when cool boxes
were opened frequently. Temperatures were never above
8°C for more than 2 hours and were within the manufac-

http://www.trialsjournal.com/content/7/1/17

turer's recommended guidelines. Thus, no vaccine had to
be discarded because of temperature variation.
Resources and supplies
On an average, 389 children were vaccinated per day and
each vaccination team worked 7 hours a day for 33 days.
A total of 12,837 vaccine doses were opened during the
vaccination campaign. Seven doses were not used because
the needle was injected in the vein.

Discussion
The results of the program in two Karachi squatter settlements show that a large-scale vaccination program has
good acceptance (74% vaccine coverage) and poses no
major safety problems. The cold chain was maintained
throughout the study in acceptable ranges. Thus, a mass
vaccination campaign in squatter settlements is logistically feasible and safe.
Improved sanitation and food hygiene are the long-term
solutions for reducing or eliminating typhoid fever [18]
but these approaches are linked to socio-economic
progress, which is slow in areas endemic for the disease.
Hence large immunization schemes as public health
measures are being recommended [9].
Some suggestions and plans for adoption based on our
trial are considered below:
Sample size
The targeted sample size could not be achieved due to
refusals and non-response during the vaccination campaign. Since; the target population in the study setting was
lower than expected. The effect of decreased coverage on
the power of the study and hence on the result was obvious. Therefore in consultation with a team of statisticians
the number of clusters was increased to 120 and the study
was extended in another setting of Karachi with comparable socio-economic characteristics. In 2004 in a separate
vaccination campaign we were able to vaccinate 14406
children of the similar age group from the remaining 60
clusters. In this way the targeted sample size was achieved.
However it is very important that careful assessment of
factors that affect response in needed in future trials to
overcome problems that affect statistical power.
Community involvement
First, the community mobilization strategy is pivotal. The
information dissemination strategy, which was based on
early stage involvement of community members with
project personnel, provided frequent opportunities for
clarifying misconceptions. This, in turn, brought about
unprecedented community rapport and response. Community leaders took children to the vaccination posts
when their mothers or female guardians were unable to
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Table 2: Demographic Data of study population present at the time of Mass Vaccination Campaign by area of residence in Karachi,
Pakistan – 2003

Hijrat

Total
Gender
Male
Female
Age group, yrs
<5
5 – 10
> 10

Sultanabad

Total

Received vaccine

%

Total

Received vaccine

%

Total

Received vaccine

%

17,340

12,830

74

9,832

7,160

73

7,508

5,670

76

9,232
8,108

6,767
6,063

73
75

5,139
4,693

3,701
3,459

72
74

4,093
3,415

3,066
2,604

75
76

4,788
7,909
4,643

3,585
6,149
3,096

75
78
67

2,546
4,553
2,733

1,881
3,518
1,761

74
77
64

2,242
3,356
1,910

1,704
2,631
1,335

76
78
70

do so and facilitated the vaccination of teenage girls. More
intensive campaigns in areas with low vaccine uptake,
areas that are politically and religiously unique from other
clusters could increase coverage.
Although refusals rates were high in this vaccination campaign no direct resistance was seen. Some of the concerns
mentioned included; 1) Why has this site been chosen for
the trial, 2) Why are vaccines coded? 3) Why is the vaccine
given for free? These concerns were dealt with by senior
field staff. A senior person from the team would visit the
household to answer questions. The questions that were
asked for the first time were then added to our list of frequently asked questions and were discussed in the next
interaction with the community.
Religious leaders have a significant influence on the intervention projects in developing countries, especially in
Muslim majority populations. We interacted with them
during the campaign after realizing the religious concerns
of the people. The religious institutes such as mosques
should be involved as part of community mobilization
plan very early in the project.
Nevertheless we are aware the trial nature of the vaccination process could have impinged on the coverage results.
Collectively those who refused to participate in the trial
(15%) and those present and did not show-up (10%)
make up a significant proportion of the target population
(25%). The parents who refused to vaccinate their children were hesitant to give their children a vaccine with a
code, despite detailed information was provided to them
by the project staff. Out side trial conditions the refusal
rate is therefore expected to be lower.
Cost-effectiveness
Cost-effectiveness or cost-benefit of Vi PS for Pakistan is
critical to convince decision-makers to finance public sector use of a new vaccine. Data from slums in New Delhi,

India, indicate that typhoid fever is a disease with high
economic consequences where the direct costs of the disease was more than US $100 per hospitalized typhoid
fever episode. More than half of these costs come directly
"out of pocket" rather than through government subsidies
[19]. Another vaccine policy analysis in the area also suggests that a vaccine such as Vi PS would provide cost-saving to society [20]. Current results from this trial suggest
the logistic feasibility, but it is understood that quantification and cost-estimation would be an important factor in
terms of acceptance by the government.
Implementation outside of EPI program
Vi PS vaccine, which does not induce immunological
memory [4], is probably not a long-term vaccine option
for Pakistan and other typhoid fever-endemic countries
for that matter. Recently a Vi conjugate vaccine was shown
to have high efficacy (89%) in Vietnamese children (ages
2–5 years) 46 months after immunization [21]. This vaccine potentially could provide long-term protection. Until
the commercial availability of this vaccine, it will be
important to consider alternative delivery scheme using
the currently available typhoid vaccine. The trial has
shown that approaching the population at risk – children
aged 2 to 16 – through a mass immunization campaign
was feasible.
Timing of the campaign
The reported campaign took place at the end of school
vacations when many households were visiting outside
the study area. There were a significant (13%) proportion
of migration between the census and the vaccine campaign (6-month period) but these findings should not be
regarded as an impediment to the introduction of a Vi PS
campaign.

Conclusion
The introduction of new vaccines into developing countries, in particular to the most impoverished, requires
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Table 3: Details of logistics used during the vaccination campaign
in Karachi – Pakistan 2003
Forms

First Aid Box

Basket

Record book
Member list
Household list
ID card (undistributed)
Informed consent
Daily logistics
Temperature chart
Transfer sheet
Progress sheet
Tally sheet
Attendance sheet
Immunogenicity
Economics
IAE
AE definition
Icebox
Icepacks
Replacement
Thermometer

Blood collection tubes
Syringes (5 ml)
Tube stand
Tourniquit
Butterfly needles
Inj Epinephrine
Inj Dexomethazone
Syringes (1 ml)
Scissors
Handiplast
Thermometer
Extra needles
Soap
Shoulder bag
Pen
Marker
Notepad
Stamp pad
Duct tape

Resuscitator
Spirit swabs
Cotton balls
Disposable gloves
Disposal bags
Lamp
Additional supply
Umbrella
Fan
Water cooler
Others
Safety box
Juices

basic research, clinical evaluations, epidemiological
assessments, policy and economic research, establishment
of production facilities, sound regulatory systems, procurement mechanisms, and distribution capabilities
[22,23] In areas where typhoid fever is a serious and widespread problem, Vi PS vaccination appears to be the most
promising available strategy for the control of typhoid
fever in the short and mid term. The mass vaccination
campaign described here showed that conducting a mass
immunization outside of the EPI program and infrastructure is feasible and acceptable, and could potentially be
implemented in a public health system.

the data computerization software and assisted in data
analysis – MA designed the data computerization software, helped in data analysis plan and assisted in data
analysis – SMW coordinated the campaign and supervised
the adverse event follow up – MJK supervised the surveillance for adverse events and coordinated the community
mobilization – RAE was involved in design and development of procedure manuals – BI was involved in design
and planning – CMG was involved in design and also
planned the laboratory procedures – TP was involved in
design and planning – AD designed the analysis plan,
stratification and randomization – LvS was involved in
planning, designing, and conduct of the study – CJA was
involved in design, conduct, analysis, drafting the manuscript – JC conceived the study and was involved in design
and conduct – SQN was involved in design and conduct –
ZAB supervised the planning, design and implementation
phase.
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